Financhill
Buy
70

ABBV Quote, Financials, Valuation and Earnings

Last price:
$202.13
Seasonality move :
3.69%
Day range:
$200.02 - $203.98
52-week range:
$153.58 - $207.32
Dividend yield:
3.11%
P/E ratio:
84.20x
P/S ratio:
6.36x
P/B ratio:
107.29x
Volume:
5.8M
Avg. volume:
5.9M
1-year change:
15.38%
Market cap:
$356.7B
Revenue:
$56.3B
EPS (TTM):
$2.40

Analysts' Opinion

  • Consensus Rating
    AbbVie has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 10 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $204.43, AbbVie has an estimated upside of 1.16% from its current price of $202.08.
  • Price Target Downside
    According to analysts, the lowest downside price target is $165.00 representing 18.35% downside risk from its current price of $202.08.

Fair Value

  • According to the consensus of 21 analysts, AbbVie has 1.16% upside to fair value with a price target of $204.43 per share.

ABBV vs. S&P 500

  • Over the past 5 trading days, AbbVie has overperformed the S&P 500 by 6.22% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • AbbVie does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • AbbVie has grown year-over-year revenues for 4 quarters straight. In the most recent quarter AbbVie reported revenues of $15.1B.

Earnings Growth

  • AbbVie earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter AbbVie reported earnings per share of -$0.02.
Enterprise value:
418.4B
EV / Invested capital:
--
Price / LTM sales:
6.36x
EV / EBIT:
64.13x
EV / Revenue:
7.43x
PEG ratio (5yr expected):
--
EV / Free cash flow:
23.46x
Price / Operating cash flow:
20.09x
Enterprise value / EBITDA:
28.06x
Gross Profit (TTM):
$39.4B
Return On Assets:
3.04%
Net Income Margin (TTM):
7.59%
Return On Equity:
61.64%
Return On Invested Capital:
5.68%
Operating Margin:
0.56%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $58.1B $54.3B $56.3B $14.3B $15.1B
Gross Profit $40.6B $33.9B $39.4B $8.6B $10.7B
Operating Income $18.8B $13.5B $11.9B $3.5B $84M
EBITDA $24.2B $17.2B $14.9B $3.9B $535M
Diluted EPS $6.61 $2.73 $2.40 $0.46 -$0.02
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $24.2B $27.9B $28.5B $33B $25.6B
Total Assets $150.6B $146.5B $138.8B $134.7B $135.2B
Current Liabilities $28.7B $35.2B $29.5B $37.8B $38.7B
Total Liabilities $137.5B $131.1B $121.5B $124.3B $131.8B
Total Equity $13.1B $15.4B $17.3B $10.4B $3.4B
Total Debt $86.1B $76.7B $63.3B $59.4B $67.1B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations $24.9B $22.8B $18.8B $4.8B $7B
Cash From Investing -$623M -$2B -$20.8B -$800M -$1.9B
Cash From Financing -$24.8B -$17.2B -$5.2B -$4.4B -$6.9B
Free Cash Flow $24.2B $22.1B $17.8B $4.5B $6.8B
ABBV
Sector
Market Cap
$356.7B
$43.6M
Price % of 52-Week High
97.47%
47.61%
Dividend Yield
3.11%
0%
Shareholder Yield
3.63%
-0.67%
1-Year Price Total Return
15.38%
-34.6%
Beta (5-Year)
0.579
0.747
Dividend yield:
3.11%
Annualized payout:
$6.20
Payout ratio:
257.71%
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $195.96
200-day SMA
Buy
Level $180.85
Bollinger Bands (100)
Buy
Level 173.32 - 194.44
Chaikin Money Flow
Buy
Level 1B
20-day SMA
Buy
Level $188.51
Relative Strength Index (RSI14)
Buy
Level 77.27
ADX Line
Buy
Level 36.93
Williams %R
Sell
Level -8.6827
50-day SMA
Buy
Level $180.71
MACD (12, 26)
Buy
Level 5.78
25-day Aroon Oscillator
Buy
Level 84
On Balance Volume
Neutral
Level 1.5B

Financial Scores

Hold
Altman Z-Score (Annual)
Level (1.8054)
Sell
CA Score (Annual)
Level (-2.1465)
Buy
Beneish M-Score (Annual)
Level (-3.0743)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (1.6156)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)

Revenue Forecast

Earnings per Share Forecast

Company Profile

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Stock Forecast FAQ

In the current month, ABBV has received 11 Buy ratings 10 Hold ratings, and 0 Sell ratings. The ABBV average analyst price target in the past 3 months is $204.43.

  • Where Will AbbVie Stock Be In 1 Year?

    According to analysts, the consensus estimate is that AbbVie share price will rise to $204.43 per share over the next 12 months.

  • What Do Analysts Say About AbbVie?

    Analysts are divided on their view about AbbVie share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AbbVie is a Sell and believe this share price will drop from its current level to $165.00.

  • What Is AbbVie's Price Target?

    The price target for AbbVie over the next 1-year time period is forecast to be $204.43 according to 21 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 10 analysts rate the stock a Hold.

  • Is ABBV A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for AbbVie is a Buy. 11 of 21 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of ABBV?

    You can purchase shares of AbbVie via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AbbVie shares.

  • What Is The AbbVie Share Price Today?

    AbbVie was last trading at $202.13 per share. This represents the most recent stock quote for AbbVie. Yesterday, AbbVie closed at $202.08 per share.

  • How To Buy AbbVie Stock Online?

    In order to purchase AbbVie stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will AMD Beat the S&P 500?
Will AMD Beat the S&P 500?

High-performance and adaptive computing leader Advanced Micro Devices (NASDAQ:AMD) is…

Why Did Walmart Stock Fall?
Why Did Walmart Stock Fall?

Walmart (NYSE:WMT) tumbled in spite of strong Q4 results that…

Is Cadence Stock a Buy, Sell or Hold?
Is Cadence Stock a Buy, Sell or Hold?

Cadence Design Systems (NASDAQ:CDNS) has seen its stock move sharply…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Sell
2
GLOB alert for Feb 22

Globant SA [GLOB] is down 27.81% over the past day.

Sell
42
CELH alert for Feb 22

Celsius Holdings [CELH] is up 27.77% over the past day.

Buy
60
HIMS alert for Feb 22

Hims & Hers Health [HIMS] is down 25.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock